Evidence map›Paper›PMID 42390178›Full record

ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2026

GWAS of Second-Generation Antihistamine Use: Locus Specificity and Highlighted Signalling Pathways.

M Niemi, S Ruotsalainen, E Saarentaus, I Vähätalo, F FinnGen, I Starskaia, T Harju, M Pelkonen, T Feuth, P Kauppi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

M NiemiInstitute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.
S RuotsalainenInstitute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.
E SaarentausInstitute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-8475-7187
I VähätaloTampere University Respiratory Research Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID https://orcid.org/0000-0003-0962-8446
F FinnGenInstitute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.
I StarskaiaTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID https://orcid.org/0000-0003-4349-439X
T HarjuOulu University Hospital, The Wellbeing Services County of North Ostrobothnia and University of Oulu, Oulu, Finland.ORCID https://orcid.org/0000-0003-4564-315X
M PelkonenKuopio University Hospital, Kuopio, Finland.
T FeuthDepartment of Pulmonary Diseases and Allergology, Turku University Hospital and University of Turku, Turku, Finland.ORCID https://orcid.org/0000-0001-6691-556X
P KauppiDepartment of Pulmonary Diseases and Allergology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-1065-330X
J PartanenResearch and Development, Finnish Red Cross Blood Service, Helsinki, Finland.ORCID https://orcid.org/0000-0001-6681-4734
R LahesmaaTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID https://orcid.org/0000-0002-4782-9567
V HytönenFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID https://orcid.org/0000-0002-9357-1480
A PalotieInstitute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-2527-5874
H KankaanrantaTampere University Respiratory Research Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID https://orcid.org/0000-0001-5258-0906
T LaitinenInstitute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0009-0003-7062-8629

Funding

AbbVie Inc., Alnylam Pharmaceuticals, Inc., AstraZeneca UK Ltd, Bayer AG, Biogen MA Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Inc. (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., GlaxoSmithKline Intellectual Property Development Ltd., Johnson & Johnson Innovative Medicine Inc., Maze Therapeutics Inc., Merck Sharp & Dohme LCC, Novartis AG, Pfizer Inc. and Sanofi US Services Inc.Business Finland 4386/31/2016Business Finland 4685/31/2016
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42390178
PMCPMC13630502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.